Use of Pyridostigmine for Constipation in Diabetics
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Doctors at Mayo Clinic are doing this study to learn if pyridostigmine, a drug, affects the
speed at which food travels through the stomach, intestines and colon, and if pyridostigmine
improves constipation symptoms in patients with diabetes. Pyridostigmine has been approved by
the Food and Drug Administration (FDA) for routine clinical use, however, its use as proposed
in this study is considered investigational.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
National Center for Research Resources (NCRR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)